Dr. Ryan Michael Carr, MD, PhD

Dr. Carr practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Carr's NPI, 1366820789, was assigned on May 18, 2015. Dr. Carr holds Minnesota license 60695.

Dr. Carr's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Carr's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Carr is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Carr to 1 more hospital, 1 clinical lab and 1 hospice, each named with a free account. Dr. Carr's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carr practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Carr's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Carr is licensed in Minnesota.

Dmand AI lists breast cancer, colorectal cancer, fluid and electrolyte imbalances, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Carr treats.

CMS data shows 54,515 Medicare services from Dr. Carr across 44 procedure codes in 2024, for 513 Medicare patients. Medicare paid $1,011,831 for them. Every service was in an office.

CMS counts 513 Medicare patients who saw Dr. Carr in 2024. The largest group is 65 to 74, with 285 patients. 65% of them have high blood pressure, and 57% have high cholesterol. 4% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carr's median patient age at 69, with 50% women.

In 2024, Dr. Carr wrote 496 Medicare Part D claims for 110 patients. 80% of them were for generic drugs. CMS names the drug for 324 of them, across 13 drugs with 11 or more claims each, at $101,286 in total drug cost. In 2023, CMS named 187 claims across 8 drugs.

Dr. Carr accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carr as offering telehealth.

Dmand AI links 39 papers to Dr. Carr, published from 2015 to 2025. 2019 was the busiest year, with 8. The most frequent topics are Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal and Gene Expression Regulation, Neoplastic. Dr. Carr has published most often in Nat Commun. Dr. Carr's most frequent co-authors are Moritz Binder, MD, MPH, Abhishek Avinash Mangaonkar and Naseema Gangat, MBBS.

CMS Open Payments shows 16 general payments to Dr. Carr from 6 drug and device companies from 2022 to 2025. Food and beverage make up the largest share, 100% of the total. Celgene Corporation paid the most, $140.

Dmand AI lists 13 awards for Dr. Carr, most recently ASCO Conquer Cancer Young Investigator Award in 2022.